ClinicalTrials.gg
Status unknownNCT04265976NATSAUUpdated Feb 17, 2020

ED Hypernatremia. Prognostic Factors and Epidemiology.

An observational study in Hypernatremia, sponsored by Centre Hospitalier Universitaire de Besancon. Status unknown at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-17.

Sponsored by Centre Hospitalier Universitaire de Besancon · Observational

The sponsor has not verified this record recently (last verified Feb 2020), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
250
Ages
18 Years and older
Sex
All
01

Study summary

This study evaluate the 1-month mortality of patients who proceed a blood sample while in the ED with an hypernatremia (>145 mmol/l). This prospective study will try to show several prognostic factors, and show the epidemiology of hypernatremia in this single center evaluation.

02

Conditions studied

  • Hypernatremia

Browse trials for

03

In context

Hypernatremia

49 studies on the registry are indexed under Hypernatremia; 8 are open to participants now.

This study's planned enrollment of 250 is above the median of 200 across 12 observational studies indexed under Hypernatremia.

Browse Hypernatremia studies →

Lead sponsor

Centre Hospitalier Universitaire de Besancon is the lead sponsor of 450 studies on the registry; 97 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Probability sample

Study population

Every >18 years old patient from who a blood sample was taken in the ED with a natremia > 145 mmol/l and don't show a refusal after information.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Natremia > 145 mmol/l

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years
  • Refusal
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
250 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. one month survival

    Survival at 1 month after the blood sample at the ED

    Time frame: 1 month

07

Study locations

1 of 1 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04265976
Responsible party
Sponsor
First posted
Feb 12, 2020
Start date
Aug 26, 2019
Primary completion
May 26, 2020 (estimated)
Completion
Sep 1, 2020 (estimated)
Last update
Feb 17, 2020

Study contacts

Romain ADAM, Resident
Contact
radam@chu-besancon.fr
+33646470168

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion